<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35181219</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>11</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2352-3840</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>46</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>Canadian journal of diabetes</Title>
          <ISOAbbreviation>Can J Diabetes</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A New Clinical Utility for Tubular Markers to Identify Kidney Responders to Saxagliptin Treatment in Adults With Diabetic Nephropathy.</ArticleTitle>
        <Pagination>
          <StartPage>134</StartPage>
          <EndPage>141.e2</EndPage>
          <MedlinePgn>134-141.e2</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcjd.2021.07.004</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1499-2671(21)00207-0</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">In recent clinical studies, saxagliptin exhibited nephroprotective potential by lowering albuminuria. In this study, we aimed to determine whether these kidney effects of saxagliptin were mediated by changes in markers of kidney tubular damage, including urinary neutrophil gelatinase-associated protein (uNGAL) and liver-type fatty acid-binding protein (uL-FABP).</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Our study included 80 patients with type 2 diabetes, hypertension and mild to moderate diabetic kidney disease (DKD) with prevalent albuminuria. Patients were either randomly assigned to saxagliptin as add-on therapy or remained unchanged on their stable antidiabetic therapy as a control arm.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Saxagliptin significantly reduced uNGAL with a median change of -25.4% (interquartile range [IQR], -35.6% to -12.2%) compared with the control group (median change, -0.91%; IQR, -12% to 11.88%; p&lt;0.001) after 3 months. Similarly, patients given saxagliptin had a highly significant reduction in uL-FABP (median change, -24.4%; IQR, -30.5% to -15.1%) compared with controls (median change, -3.8%; IQR -10% to 12.5%; p&lt;0.001). Median estimated glomerular filtration rate (eGFR) values after 3 months in the saxagliptin arm were significantly higher (76.5 mL/min per 1.73 m<sup>2</sup>; IQR, 70 to 92.75 mL/min per 1.73 m<sup>2</sup>) in the low-risk uNGAL group compared with controls (59.8 mL/min per 1.73 m<sup>2</sup>; IQR, 51 to 76.2 mL/min per 1.73 m<sup>2</sup>; p=0.002). Also, higher-although not significantly-posttreatment eGFR levels were observed in patients with low risk of uL-FABP (73 mL/min per 1.73 m<sup>2</sup>; IQR, 58 to 91.3 mL/min per 1.73 m<sup>2</sup>) compared with controls (57.3 mL/min per 1.73 m<sup>2</sup>; IQR, 49.5 to 72.6 mL/min per 1.73 m<sup>2</sup>; p=0.06). No significant increase was observed in high-risk patients for either marker when compared with controls.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The albuminuria-lowering effect of saxagliptin may be due to inhibition of kidney tubular damage. Use of tubular markers may be a promising approach to identifying kidney responders to gliptins.</AbstractText>
          <CopyrightInformation>Copyright © 2021 Canadian Diabetes Association. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Mohsen</LastName>
            <ForeName>Marwa</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmacy, Clinical Pharmacy Department, Beni-Suef University, Beni-Suef, Egypt. Electronic address: marwa.mohseneldawy90@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Elberry</LastName>
            <ForeName>Ahmed A</ForeName>
            <Initials>AA</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, Clinical Pharmacology Department, Beni-Suef University, Beni-Suef, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rabea</LastName>
            <ForeName>Alaa Mohamed</ForeName>
            <Initials>AM</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, Internal Medicine and Nephrology Department, Beni-Suef University, Beni-Suef, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Khalil</LastName>
            <ForeName>Doaa Mahmoud</ForeName>
            <Initials>DM</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine, Public Health and Community Medicine Department, Beni-Suef University, Beni-Suef, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Abdelrahim</LastName>
            <ForeName>Mohamed E A</ForeName>
            <Initials>MEA</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmacy, Clinical Pharmacy Department, Beni-Suef University, Beni-Suef, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hussein</LastName>
            <ForeName>Raghda R S</ForeName>
            <Initials>RRS</Initials>
            <AffiliationInfo>
              <Affiliation>Faculty of Pharmacy, Clinical Pharmacy Department, Beni-Suef University, Beni-Suef, Egypt; Clinical Pharmacy Department, Faculty of Pharmacy, Modern University for Technology and Information, Cairo, Egypt.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>08</Month>
          <Day>02</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Canada</Country>
        <MedlineTA>Can J Diabetes</MedlineTA>
        <NlmUniqueID>101148810</NlmUniqueID>
        <ISSNLinking>1499-2671</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9GB927LAJW</RegistryNumber>
          <NameOfSubstance UI="C502994">saxagliptin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PJY633525U</RegistryNumber>
          <NameOfSubstance UI="D000218">Adamantane</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000218" MajorTopicYN="N">Adamantane</DescriptorName>
          <QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000419" MajorTopicYN="N">Albuminuria</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003928" MajorTopicYN="Y">Diabetic Nephropathies</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005919" MajorTopicYN="N">Glomerular Filtration Rate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">DKD</Keyword>
        <Keyword MajorTopicYN="N">NPD</Keyword>
        <Keyword MajorTopicYN="N">responders</Keyword>
        <Keyword MajorTopicYN="N">répondeurs</Keyword>
        <Keyword MajorTopicYN="N">saxagliptin</Keyword>
        <Keyword MajorTopicYN="N">saxagliptine</Keyword>
        <Keyword MajorTopicYN="N">uL-FABP</Keyword>
        <Keyword MajorTopicYN="N">uNGAL</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>19</Day>
          <Hour>5</Hour>
          <Minute>27</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35181219</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jcjd.2021.07.004</ArticleId>
        <ArticleId IdType="pii">S1499-2671(21)00207-0</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
